Program: Education Program
Session: Thrombosis Prevention and Treatment
Hematology Disease Topics & Pathways:
Clinical Trials, Workforce, Diversity, Equity, and Inclusion (DEI) , drug development, Therapies
Session: Thrombosis Prevention and Treatment
Hematology Disease Topics & Pathways:
Clinical Trials, Workforce, Diversity, Equity, and Inclusion (DEI) , drug development, Therapies
Monday, December 12, 2022, 4:30 PM-5:45 PM
Disclosures: Ageno: Norgine: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Viatris: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Honoraria; BMS-Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Leo Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees.
<< Previous Presentation
|
Next Presentation